By Professor Ric Day

Journal articles

Hancock M; Maher C; Latimer J; Mclachlan AJ; Cooper C; Day RO; Spindler M; McAuley J, 2005, 'Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]', BMC Musculoskeletal Disorders, 6

Henry D; Kerridge IH; Hill S; Mcneill PM; Doran E; Newby D; Henderson K; Maguire J; Stokes B; Macdonald GJ; Day RO, 2005, 'Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience', Medical Journal of Australia, 182, pp. 557 - 560

Day RO; Graham GG, 2005, 'Paracetamol should be first-line therapy in osteoarthritis', Medical Journal of Australia, 182, pp. 198 - 199

Kaye KI; Welch SA; Graudins LV; Graudins A; Rotem T; Davis S; Day RO, 2005, 'Pethidine in emergency departments: promoting evidence-based prescribing', Medical Journal of Australia, 183, pp. 129 - 133

Lu CY; Ritchie JE; Williams KM; Day RO, 2005, 'Recent developments in targeting access to high cost medicines in Australia', Australia and New Zealand Health Policy, 2, pp. 1 - 8

Ritchie JE; Lu CY; Williams K; Day RO, 2005, 'Sample size is beside the point in policy development research', Australian and New Zealand Journal of Public Health, 29, pp. 583 - 583

Hamama A; Ray J; Day RO; Brien JE, 2005, 'Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography', Journal of Chromatographic Science, 43, pp. 351 - 354

Lassere MN; Johnson KR; Boers M; Carlton KE; Day RO; Wit M; Edwards I; Fries J; Furst DE; Kirwan J; Tugwell P; Woodworth G; Brooks P, 2005, 'Standardized Assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module Update', Journal of Rheumatology, 32, pp. 2037 - 2041

Lu CY; Ritchie JE; Williams KJ; Day RE, 2005, 'Targeted access to high-cost medicines in Australia: Early analysis from a qualitative study', Value in Health, 8, pp. A28 - A28

Henry D; Doran E; Kerridge IH; Hill SB; Mcneill PM; Day RO, 2005, 'Ties that bind - Multiple relationships between clinical researchers and the pharmaceutical industry', Archives of Internal Medicine, 165, pp. 2493 - 2496

Graham GG; Day RO, 2005, 'Tolerability of paracetamol', Drug Safety, 28, pp. 227 - 240

Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ, 2004, 'Erratum: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (British Journal of Clinical Pharmacology (2004) 57 (592-599))', British Journal of Clinical Pharmacology, 58, pp. 102, http://dx.doi.org/10.1111/j.1365-2125.2004.02155.x

Day RO; Graham GG, 2004, 'The vascular effects of COX-2 selective inhibitors', Australian Prescriber, 27, pp. 142 - 145, http://dx.doi.org/10.18773/austprescr.2004.119

Day RO; Brooks P; Conaghan PG; Petersen M, 2004, 'A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee', Journal of Rheumatology, 31, pp. 775 - 782

Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; Mcphee D; Mclachlan AJ; Gelder F; Lewin S; Liauw WS; Williams KM, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals', HIV Clinical Trials, 5, pp. 91 - 98

Lu CY; Williams KM; Day RO; March LM; Sansom L; Bertouch JV, 2004, 'Access to high cost drugs in Australia', British Medical Journal: Clinical Research, 329, pp. 415 - 416

Jiang XM; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; Mclachlan AJ, 2004, 'Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, 57, pp. 592 - 599

Jiang XM; Williams KM; Liauw WS; Ammit A; Roufogalis B; Duke C; Day RO; Mclachlan AJ, 2004, 'Pharmacokinetic-pharmacodynamic modelling to investigate herb-drug interactions with warfarin', Clinical and Experimental Pharmacology and Physiology, 31, pp. A227 - A227

Liauw WS; Williams KM; Day RO, 2004, 'Protocol Appraisal: A Study Site's Viewpoint', Applied Clinical Trials, 13, pp. 34 - 42

Tan E; Day RO; Brien JE, 2004, 'Stakeholder Opinions on the Implementation of Drug and Therapeutics Committee Decisions', Journal of Pharmacy Practice and Research, 34, pp. 178 - 182

Lee EJ; Williams KM; Day RO; Graham GG; Champion D, 2004, 'Stereoselective disposition of ibuprofen enantiomers in man (Reprintedfrom Br J Clin Pharmacol, vol 19, pg 669-674, 1985)', British Journal of Clinical Pharmacology, 58, pp. S759 - S764

Graham GG; Scott KF; Day RO, 2003, 'Tolerability of Paracetamol', Drugs, 63, pp. 43 - 46, http://dx.doi.org/10.2165/00003495-200363992-00007

Day R, 2003, 'COX-2: Where are we in 2003? Distinction from NSAIDs becoming blurred', Arthritis Research and Therapy, 5, pp. 116 - 119

Graham GG; Scott KF; Day RO, 2003, 'Tolerability of paracetamol', DRUGS, 63, pp. 43 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000186278900006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Liauw WS; Day RO, 2003, 'Adverse event reporting in clinical trials: room for improvement', Medical Journal of Australia, 179, pp. 426 - 428

Graham GG; Scott KF, 2003, 'Alcohol and paracetamol', Australian Prescriber, 27, pp. 14 - 15

Tan E; Day RO; Brien JE, 2003, 'Drug and therapeutics committees - are they fulfilling their potential to improve the quality use of medicines?', International Journal of Pharmacy Practice, 11, pp. 175 - 181

Sasongko L; Williams KM; Day RO; Mclachlan AJ, 2003, 'Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques', British Journal of Pharmacology, 56, pp. 551 - 561

Day RO, 2003, 'Hypertension in the patient with arthritis: Have we underestimated its significance?', Journal of Rheumatology, 30, pp. 642 - 644

Day RO, 2003, 'Pharmaceutical health and rational use of medicines committee', Journal of Pharmacy Practice and Research, 33, pp. 87 - 89

Wren BG; Day RO; Mclachlan AJ; Williams KM, 2003, 'Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women', Climacteric, 6, pp. 104 - 111

Day RO, 2003, 'Where are we in 2003? Distinction from NSAIDs becoming blurred', Arthritis Research and Therapy, 5, pp. 116 - 119

Edmonds JP; Day RO; Bertouch JV, 2002, 'The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors - Reply', MEDICAL JOURNAL OF AUSTRALIA, 177, pp. 573 - 573, http://dx.doi.org/10.5694/j.1326-5377.2002.tb04961.x

Vitry AI; Hurley E; Gazarian M; Kaye KI; Edmonds JP; Day RO; Bertouch JV, 2002, 'The road to consensus: Considerations for the safe use and prescribing of COX-2-specific inhibitors (multiple letters)', Medical Journal of Australia, 177, pp. 572 - 573, http://dx.doi.org/10.5694/j.1326-5377.2002.tb04959.x

Carmichael SJ; Beal J; Day RO; Tett SE, 2002, 'Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate', Journal of Rheumatology, 29, pp. 2077 - 2083

Day R, 2002, 'Adverse reactions to TNF-α inhibitors in rheumatoid arthritis', Lancet, 359, pp. 540 - 541, http://dx.doi.org/10.1016/S0140-6736(02)07718-8

Day R, 2002, 'Another selective COX-2 inhibitor: More questions than answers?', Journal of Rheumatology, 29, pp. 1581 - 1582

Day RE; Higgins VJ; Rogers PJ; Dawes IW, 2002, 'Characterisation of the putative maltose transporters encoded by YDL247w and YJR160c', Yeast, 19, pp. 1015 - 1027

Graham GG; Graham RM; Day RO, 2002, 'Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol)', Current Pharmaceutical Design, 8, pp. 1063 - 1075

Barraclough D; Bertouch J; Brooks P; Brown MA; Cleland L; Clemens LE; Crowley SJ; Day RO; DeJager JP; Edmonds JP; Fletcher P; Franks GR; Harris DC; Horowitz JD; Johnston MD; Kerr SJ; Littlejohn GO; Macdonald GJ; McColl GJ; Sambrook PN; Shakib S; Verso MW; Yeomans ND, 2002, 'Considerations for the safe prescribing and use of COX-2-specific inhibitors', Medical Journal of Australia, 176, pp. 328 - 331

Day RE; Rogers PJ; Dawes IW; Higgins VJ, 2002, 'Molecular Analysis of Maltotriose Transport and Utilisation by Saccharomyces cerevisiae', Applied and Environmental Microbiology, 68, pp. 5326 - 5335

Edmonds JP; Day RO; Bertouch JV, 2002, 'The road to consensus: considerations for the safe use and prescribing of COX-2 specific inhibitors', Medical Journal of Australia, 176, pp. 332 - 334

Brooks PM; Day RO, 2001, 'OMERACT 5 Drug Safety Working Group Report: Introduction', JOURNAL OF RHEUMATOLOGY, 28, pp. 1162 - 1162, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000168487900043&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Brooks PM; Day RO, 2001, 'COX-2 inhibitors - In reply', MEDICAL JOURNAL OF AUSTRALIA, 174, pp. 368 - 369, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143324.x

Lawrie MM; McKeough GN; Jones DB; Brooks PM; Day RO, 2001, 'COX-2 inhibitors (multiple letters)', Medical Journal of Australia, 174, pp. 367 - 369, http://dx.doi.org/10.5694/j.1326-5377.2001.tb143321.x

Brooks PM; Day RO, 2001, 'Drug safety module: Summary and recommendations', Journal of Rheumatology, 28, pp. 1192 - 1193

Lipani JA; Strand V; Johnson KA; Woodworth T; Furst DE; Singh G; Day RO; Brooks PM, 2001, 'OMERACT Drug Safety Working Party. A proposal for developing a large ptient population cohort for longterm safety monitoring in rheumatoid arthritis.', Journal of Rheumatology, pp. 1170 - 1173

Welch V; Singh G; Strand V; Fries JW; Boers M; Ramey D; Day RO; Brooks PM; Tugwell P; Clinch J; Kristjansson B, 2001, 'Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index', Journal of Rheumatology, pp. 1188 - 1191

Day RO, 2001, 'Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: A rheumatologists perspective', Clinical and Experimental Rheumatology, 19, pp. 59 - 62

Day RO; Mashford ML, 2001, 'Pharmacotherapeutics: what a difference five decades makes!', Medical Journal of Australia, 174, pp. 48 - 51

Back to profile page